Interacting Drugs |
Ganciclovir (systemic) vs Reverse Transcriptase Inhibitors (Nucleoside) |
Security Level |
 |
Mechanism |
Reverse Transcriptase Inhibitors (Nucleoside): Ganciclovir-Valganciclovir may enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern. Exceptions: Stavudine. |
Management |
Consider therapy modification |
Ganciclovir (systemic) vs Reverse Transcriptase Inhibitors (Nucleoside)
Post Review about Ganciclovir (systemic) vs Reverse Transcriptase Inhibitors (Nucleoside) Click here to cancel reply.
Other Interactions of Ganciclovir (systemic)
Other Interactions of Reverse Transcriptase Inhibitors (Nucleoside)
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.